Biotech | March 10, 2022
Pfizer initiates Phase2/3 study of Paxlovid in pediatric participants
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
It is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Routine tests undertaken by women dropped by 35% in 2020
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
The revolutionary genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age
It plans launch various other health monitoring tools for smartphones, making existing devices obsolete
A total of 17 labs will be operational across the country by this month
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Subscribe To Our Newsletter & Stay Updated
